Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease

Erasmus MC, University Medical Center, Department of Neurology, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Neuromuscular Disorders (Impact Factor: 3.13). 02/2009; 19(2):113-7. DOI: 10.1016/j.nmd.2008.11.007
Source: PubMed

ABSTRACT To determine the rate of disease progression in patients with late-onset Pompe disease, we collected longitudinal data on pulmonary function and skeletal muscle strength in 16 patients whose symptoms had started in childhood or adulthood. The mean duration of follow-up was 16 years (range 4-29 years). During the follow-up period, eight patients (50%) became wheelchair bound and three (19%) became ventilator dependent. At a group level, pulmonary function deteriorated by 1.6% per year, and proximal muscle weakness progressed gradually. At the individual level, however, the rate and extent of progression varied highly between patients. In two thirds of patients, pulmonary function and muscle strength declined simultaneously and to the same extent. The remaining one third of patients showed a variable, sometimes rapidly progressive course, leading to early respirator or wheelchair dependency. These individual differences, especially in pulmonary dysfunction, indicate the need for regular monitoring every 6-12 months depending on the rate of disease progression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, an attempt has been made to differentiate sEMG signals under muscle fatigue and non-fatigue conditions using multiscale features. Signals are recorded from biceps brachii muscle of 50 normal adults during repetitive dynamic contractions. After prescribed preprocessing, each signal is divided into six segments out of which first and last segments are considered in this analysis. Multiscale RMS (MSRMS) and Multiscale Permutation Entropy (MSPE) are computed for each subject in the time scales ranging from 1 to 50. The median values of the MSRMS and MSPE are calculated for further analysis. The results show an increase in amplitude for sEMG signals under fatigue condition. MSRMS values are found to be significantly higher in fatigue. An approximately constant difference in MSRMS value between fatigue and non-fatigue condition is observed over the entire time scale with a negative slope. Further, the median of MSRMS values for each subject is able to distinguish fatigue and non-fatigue conditions. Similar analysis on MSPE showed significant difference between fatigue and non-fatigue cases and lower values of MSPE is observed in fatigue. It is also observed that the median value of MSRMS and MSPE are able to distinguish these conditions. t-test for MSRMS, MSPE and their median value show high statistical significance. It appears that this method of analysis can be used for clinical evaluation of muscles.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine the frequency and impact of gastrointestinal symptoms, and bowel and urinary incontinence, as this is currently unknown in adults with Pompe disease. Methods: Adult German Pompe patients and age- and gender-matched controls were asked about symptoms in the upper and lower intestinal tract as well as urinary incontinence using the Gastrointestinal Symptoms Questionnaire and the International Consultation on Incontinence Questionnaires for Bowel Symptoms and Urinary Incontinence. Results: The overall response rate was 78%; 57 patients and 57 controls participated. The mean age of the patients was 48.3 years ±14.7 (28 female, 29 male). 84% of patients were receiving enzyme replacement therapy. Stool urgency, diarrhoea, and urinary urge incontinence were reported significantly more frequently in patients compared to the age- and gender-matched controls (55%, 56%, 33% vs. 20%, 18%, 7%). 20% of Pompe patients used loperamide daily against diarrhoea. No other gastrointestinal tract-related symptoms were reported to occur more frequently in Pompe patients than in controls. Conclusions: Compared to age- and gender-matched controls, both urinary and bowel incontinence occur in a higher frequency in adults with Pompe disease and have a major impact on daily life.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Enzyme replacement therapy (ERT) with recombinant human alglucosidase alfa (rhGAA) in late-onset Pompe disease is moderately effective. Little is known about the clinical course after treatment termination and the resumption of ERT. In Switzerland, rhGAA therapy for Pompe disease was temporarily withdrawn after the federal court judged that the treatment costs were greatly out of proportion compared to the benefits. Re-treatment was initiated after the therapy was finally licensed. We retrospectively analysed seven Pompe patients, who underwent cessation and resumption of ERT (median age 43 years). The delay from first symptoms to final diagnosis ranged from 4 to 20 years. The demographics, clinical characteristics, assessments with the 6-min walking test (6-MWT), the predicted forced vital capacity (FVC) and muscle strength were analysed. Before initiation of ERT, all patients suffered from proximal muscle weakness of the lower limbs; one was wheelchair-bound and two patients received night-time non-invasive ventilation. Initial treatment stabilised respiratory function in most patients and improved their walking performance. After treatment cessation, upright FVC declined in most and the 6-MWT declined in all patients. Two patients needed additional non-invasive ventilatory support. Twelve months after resuming ERT, the respiratory and walking capacity improved again in most patients. However, aside for one patient, none of the patients reached the same level of respiratory function or distance walked in 6 min, as at the time of ERT withdrawal. We conclude that cessation of ERT in Pompe disease causes a decline in clinical function and should be avoided. Resuming treatment only partially recovers respiratory function and walking capacity.
    Journal of Neurology 06/2014; 261(9). DOI:10.1007/s00415-014-7402-z · 3.84 Impact Factor